60NANB22D168
Project Grant
Overview
Grant Description
Purpose: The purpose of this project is to use machine learning and other advanced computational methods to accelerate the therapeutic drug discovery process.
Activities to be performed: The researchers will acquire and implement a high-performance data analytic and computing infrastructure at the University at Buffalo (UB). They will use this infrastructure to apply the Computational Analysis of Novel Drug Opportunities (CANDO) platform to discover and design therapeutic drug therapies to treat a variety of high priority diseases.
Expected outcomes: The project expects to rapidly identify novel compounds with the potential to be used as therapeutics. In addition, this facility will improve research, training, and education activities at UB.
Intended beneficiaries: This is to acquire a high-performance data analytic infrastructure to support a computational drug discovery platform. This will lead to commercialization of new drugs for patient use benefiting the US pharmaceutical industry, public, and researchers interested in drug discovery methods.
Subrecipient activities: The recipient does not intend to subaward funds.
Activities to be performed: The researchers will acquire and implement a high-performance data analytic and computing infrastructure at the University at Buffalo (UB). They will use this infrastructure to apply the Computational Analysis of Novel Drug Opportunities (CANDO) platform to discover and design therapeutic drug therapies to treat a variety of high priority diseases.
Expected outcomes: The project expects to rapidly identify novel compounds with the potential to be used as therapeutics. In addition, this facility will improve research, training, and education activities at UB.
Intended beneficiaries: This is to acquire a high-performance data analytic infrastructure to support a computational drug discovery platform. This will lead to commercialization of new drugs for patient use benefiting the US pharmaceutical industry, public, and researchers interested in drug discovery methods.
Subrecipient activities: The recipient does not intend to subaward funds.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Buffalo,
New York
14228-2567
United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Analysis Notes
Amendment Since initial award the End Date has been extended from 10/31/23 to 10/31/24.
Research Foundation For The State University Of New York was awarded
Project Grant 60NANB22D168
worth $1,000,000
from the National Institute of Standards and Technology in November 2022 with work to be completed primarily in Buffalo New York United States.
The grant
has a duration of 2 years and
was awarded through assistance program 11.617 Congressionally-Identified Projects.
Status
(Ongoing)
Last Modified 9/11/23
Period of Performance
11/1/22
Start Date
10/31/24
End Date
Funding Split
$1.0M
Federal Obligation
$0.0
Non-Federal Obligation
$1.0M
Total Obligated
Activity Timeline
Transaction History
Modifications to 60NANB22D168
Additional Detail
Award ID FAIN
60NANB22D168
SAI Number
60NANB22D168_1
Award ID URI
EXE
Awardee Classifications
Other
Awarding Office
1333ND DEPT OF COMMERCE NIST
Funding Office
1333ND DEPT OF COMMERCE NIST
Awardee UEI
LMCJKRFW5R81
Awardee CAGE
3GQT6
Performance District
NY-26
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Scientific and Technical Research and Services, National Institute of Standards and Technology, Commerce (013-0500) | Other advancement of commerce | Grants, subsidies, and contributions (41.0) | $1,000,000 | 100% |
Modified: 9/11/23